Strategies for management of the peritoneal surface component of cancer: Cytoreductive surgery plus perioperative intraperitoneal chemotherapy

Journal of Oncology Pharmacy Practice

Volumn 11, Issue 3, 2005, Pages 111-119

  Sugarbaker, Paul H ^a   Stuart, O Anthony ^a   Yoo, Dal ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Carcinomatosis; Cisplatin; Cytoreductive surgery; Doxorubicin; Intraperitoneal chemotherapy; Mitomycin C

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DILUTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG MECHANISM; DRUG SOLUTION; DRUG TISSUE LEVEL; GYNECOLOGIC CANCER; HUMAN; HYPERTHERMIC THERAPY; MOLECULAR WEIGHT; PERIOPERATIVE PERIOD; PERITONEAL CAVITY; PERITONEUM METASTASIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENITAL NEOPLASMS, FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; INTRAOPERATIVE PERIOD; MITOMYCIN; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; POSTOPERATIVE PERIOD;

EID: 27144506650     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155205jp157oa     Document Type: Review

References (20)

1. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989; 63: 364-67.
2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Result of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-63.
3. Jayne DG, Fook S, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-50.
4. Yu W, Whang I, Young C, et al. Indications for early postoperative intraperitoneal chemotherapy for advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001; 25: 985-90.
5. Glehen O, Gilly F, Sugarbaker PH. New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? Scand J Surg 2003; 92: 178-79.
6. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-43.
7. Link KH, Roitman M, Holtappels M, et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003; 12: 865-72.
8. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In Sugarbaker PH, ed. Peritoneal carcinomatosis: principles of management, Boston, MA: Kluwer; 1996: 79-100.
9. Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22: 465-72.
10. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
11. Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev 1986; 3: 1-24.
12. Schott A, Vogel I, Krueger U, et al. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 1998; 227: 372-79.
13. Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 1985; 248: F413-F424.
14. Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10: 112-22.
15. Sugarbaker PH, Averbach AM, Jacquet P, et al. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In Sugarbaker PH, ed. Peritoneal carcinomatosis: principles of management, Boston, MA: Kluwer; 1996: 415-21.
16. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21: 799-806.
17. Mohamed F, Marchettini P, Stuart OA, et al. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 2003; 29: 261-65.
18. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol (in press).
19. Urano, M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999; 15: 79-107
20. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12: 755-69.